Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trialAditya Bardia, Allyson J. Ocean, Kevin Kalinsky et al.|Annals of Oncology|2021Cited by 371
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid TumorsAlexander Starodub, David M. Goldenberg, Allyson J. Ocean et al.|Clinical Cancer Research|2015Cited by 344
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)Dung T. Le, Elizabeth M. Jaffee, Vincent J. Picozzi et al.|Clinical Cancer Research|2019Cited by 260
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokineticsAllyson J. Ocean, David M. Goldenberg, Alexander Starodub et al.|Cancer|2017Cited by 235